Kronos Bio (NASDAQ:KRON) reported quarterly losses of $(0.50) per share which missed the analyst consensus estimate of $(0.42) by 19.05 percent. The company reported quarterly sales of $2.520 million which beat the analyst consensus estimate of $1.000 million by 152.00 percent. This is a 106.39 percent increase over sales of $1.221 million the same period last year.
Kronos Bio Q1 2024 Adj EPS $(0.50) Misses $(0.42) Estimate, Sales $2.520M Beat $1.000M Estimate
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.